Last reviewed · How we verify
Dabrafenib plus Trametinib (dabrafenib-plus-trametinib)
Dabrafenib and trametinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to prevent tumor growth.
At a glance
| Generic name | dabrafenib-plus-trametinib |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Mechanism of action
Dabrafenib targets the BRAF V600E mutation, while trametinib inhibits MEK, both part of the MAPK pathway, which is often overactive in certain cancers. Together, they effectively block the pathway, slowing or stopping cancer cell growth.
Approved indications
Common side effects
- Pyrexia
- Fatigue
- Headache
- Nausea
- Diarrhoea
- Chills
- Arthralgia
- Rash
- Vomiting
- Cough
- Asthenia
- Myalgia
Key clinical trials
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (PHASE1, PHASE2)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment (PHASE1, PHASE2)
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (PHASE2)
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer (PHASE3)
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabrafenib plus Trametinib CI brief — competitive landscape report
- Dabrafenib plus Trametinib updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI